Quick Answer
Pharming Group N.V. reported Total Assets of $399.99 million for fiscal year 2024.
Pharming Group N.V. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Assets | $399.99M -13.6% |
$462.85M +8.7% |
$425.80M +7.2% |
$397.31M +16.6% |
$340.76M +49.3% |
$228.21M |
| R&D Expense | $83.15M +20.7% |
$68.91M +31.2% |
$52.53M -25.3% |
$70.37M +82.7% |
$38.52M +35.8% |
$28.37M -1.8% |
| Gross Profit | $261.80M +18.9% |
$220.10M +17.0% |
$188.06M +5.8% |
$177.73M -5.8% |
$188.63M +27.7% |
$147.67M +30.7% |
- Pharming Group N.V. reported Total Assets of $399.99 million for fiscal year 2024.
- Pharming Group N.V. showed a decrease of -13.6% in Total Assets compared to the prior fiscal year.
- Pharming Group N.V. reported R&D Expense of $83.15 million for fiscal year 2024.
- Pharming Group N.V. showed an increase of +20.7% in R&D Expense compared to the prior fiscal year.
- Pharming Group N.V. reported Gross Profit of $261.80 million for fiscal year 2024.
- Pharming Group N.V. showed an increase of +18.9% in Gross Profit compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: